Sunshine Biopharma Inc
SBFM
View Detailed Chart
1.470USD
-0.010-0.67%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
6.70MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-0.67%
5 Days
-1.89%
1 Month
+3.52%
6 Months
-31.31%
Year to Date
-51.00%
1 Year
-55.45%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated: 2025-09-19Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
1
analysts
Buy
Current Rating
7.000
Target Price
+376.19%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Sunshine Biopharma, Inc. is a Canada-based pharmaceutical company. The Company offers and researches life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has over 32 additional generic prescription drugs. In addition, the Company is conducting a proprietary drug development program which consists of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). It also operates two wholly owned subsidiaries: NoraPharma Inc., which has a portfolio of pharmaceutical products consisting of approximately 61 generic prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells non-prescription over-the-counter (OTC) products.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 702.52% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 34.87M.
Overvalued
The company’s latest PE is 0.04, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 174.71K shares, decreasing 55.48% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 54.09K shares of this stock.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Sunshine Biopharma, Inc. is a Canada-based pharmaceutical company. The Company offers and researches life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has over 32 additional generic prescription drugs. In addition, the Company is conducting a proprietary drug development program which consists of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). It also operates two wholly owned subsidiaries: NoraPharma Inc., which has a portfolio of pharmaceutical products consisting of approximately 61 generic prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells non-prescription over-the-counter (OTC) products.
Ticker SymbolSBFM
CompanySunshine Biopharma Inc
CEODr. Steve N. Slilaty
Websitehttps://www.sunshinebiopharma.com/
Related Instruments
-1.40%
+1.17%
+0.19%
+0.48%
-1.02%
-0.71%
-0.04%
+3.47%
+0.41%
-0.50%
-0.08%
-1.03%
-1.29%
+1.22%
+0.92%
-0.92%
-0.23%
-0.83%
-1.12%
+0.31%
